ABBVIE INC. (ABBV) — Analysis Summary
ABBVIE INC. (ABBV) has a market cap of $468.22B with year-over-year revenue growth of +8.6%. Net margin stands at 6.9%. The stock trades at a P/E ratio of 74.2.
Key Takeaways
- Revenue changed +8.6% year-over-year
- Net margin of 6.9%
- P/E ratio of 74.2
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ABBV posted revenue growth of +8.6% and trades at a P/E of 74.2.
ABBVIE INC. (ABBV)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Shareholder equity is negative, which can signal balance-sheet stress.
Current ratio at 0.81x — current liabilities exceed current assets
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
57,000
Headquarters
NORTH CHICAGO, IL
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$6.92
Dividend Yield
2.61%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.